The present Competitive Intelligence report about Bruton’s Tyrosine Kinase (BTK) Inhibitorsprovides a competitor evaluation in the field of small molecule-based inhibitors of Bruton’s Tyrosine Kinase (BTK) for the treatment of B-cell related hematologic malign ancies and autoimmune diseases as of August 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of small molecule Bruton’s Tyrosine Kinase (BTK) inhibitors in oncology and inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of BTK inhibitors. Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target / Mechanism of Action
- Class of Compound
- Product Category
- R&D Stage
- additional comments with a hyperlink leading to the source of information
About theCompetitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
BTK Inhibitors in Inflammatory & Autoimmune Diseases
2. Corporate BTK Inhibitor R&D Pipelines
- Advinus Therapeutics
- Aegera Therapeutics
- Hanmi Pharmaceutical Co
- Janssen Biotech
- Ono Pharmaceutical Co.
- Tolero Pharmaceuticals